Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology, Inc. | LinkedIn
ADAPTING
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology's (PBYI) Lowest Price: $1.6400 (on 05-11-2022)
Pamela Wilson email address & phone number | Puma Biotechnology, Inc. Sr VP, Clinical Operations contact information - RocketReach
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
Puma Biotechnology, Inc. 2023 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
